Physician profile
Kenneth E Calabrese
NPI 1073601175
$704.34
in general payments reported to CMS, 2019-2025
12 companies · $13.87 in 2025
The $13.87 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $250 · 2021: $126 · 2025: $13.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $122.65 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.09 | 2020 | |
| Amgen INC. | $80.36 | 2019-2021 | |
| Vifor Pharma, INC. | $80.35 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $78.47 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $70.33 | 2020-2021 | |
| Veloxis Pharmaceuticals, INC. | $57.34 | 2020 | |
| Horizon Therapeutics Plc | $54.80 | 2019 | |
| Glaxosmithkline, LLC. | $26.22 | 2021 | |
| Genentech USA, INC. | $18.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.87 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.